A weight loss drug has been approved to treat heart disease in overweight and obese patients by Australia’s medicines regulator, in what experts say is a “new frontier for the drugs”.
The Therapeutic Goods Administration (TGA) granted approval in December 2024 for semaglutide 2.4 mg, sold under the brand name Wegovy, to be used as a complementary therapy for adults with both cardiovascular disease and high body mass index, to reduce the related risk of heart attack, stroke or death.